Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;13(4-6):169-173.
doi: 10.1080/20468954.2025.2535939. Epub 2025 Jul 22.

Trivalent bispecific anti-MSLN2/CD3 antibody for cancer treatment

Jorge Antonio Perez Saldaña  1 , Donaciano Flores-Robles  1 , Antonio Celestino Montes  1 , Alejandro Millán-Vega  1 , Pavel Sierra-Martínez  1 , Martin Perez-Santos  2
Affiliations
Review

Trivalent bispecific anti-MSLN2/CD3 antibody for cancer treatment

Jorge Antonio Perez Saldaña et al. Pharm Pat Anal. 2024.

Abstract

Introduction: Mesothelin protein is an overexpressed molecule in epithelioid mesothelioma, epithelial ovarian cancer, and pancreatic adenocarcinoma, which is why it is considered a potential therapeutic target.

Areas covered: WO2024082060 patent describes a trivalent bispecific antibody directed against MSLN/CD3/MSLN, and lung cancer treatment method. This antibody exhibits binding activity to MSLN-containing tumor cells, as well as inhibition of tumor growth rate in murine models of lung and ovarian cancer.

Expert opinion: The trispecific structure suggesting that this antibody is a potential candidate for clinical trials for the treatment of lung cancer associated with high levels of MSLN expression.

Keywords: CD3; MSLN; lung cancer; patent; trivalent bispecific antibody.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834 - DOI - PubMed
    1. Pai-Scherf L, Blumenthal GM, Li H, et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist. 2017;22(11):1392–1399. doi: 10.1634/theoncologist.2017-0078 - DOI - PMC - PubMed
    1. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–642. doi: 10.1634/theoncologist.2015-0507 - DOI - PMC - PubMed
    1. Syed YY. Durvalumab: first global approval. Drugs. 2017;77(12):1369–1376. doi: 10.1007/s40265-017-0782-5 - DOI - PMC - PubMed
    1. Mathieu L, Shah S, Pai-Scherf L, et al. FDA approval summary: atezolizumab and Durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021;26(5):433–438. doi: 10.1002/onco.13752 - DOI - PMC - PubMed

LinkOut - more resources